Last reviewed · How we verify
NCT06641817
The Value of Cardiovascular Imaging in Kawasaki Disease
trial in Kawasaki Disease in 500 participants. Enrolling by invitation.
1 January 2033
Quick facts
| Lead sponsor | West China Second University Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 September 2023 |
| Primary completion | 1 January 2033 |
| Estimated completion | 31 December 2033 |
| Sites | 1 location across China |
Conditions studied
- Kawasaki Disease — all drugs for Kawasaki Disease →
Sponsor
West China Second University Hospital
Who can join
Under 18, any sex, with Kawasaki Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to assess the cardiovascular injury of Kawasaki disease with multi-modal imaging combined with clinical data. During their disease progress, participants will undergo cardiovascular magnetic resonance, echocardiography, electrocardiography, laboratory tests, and genetic tests when hospitalization and follow-up, and the baseline data will be collected at the admission. Some patients will undergo coronary computed tomography angiography (CCTA) or DSA due to the disease progress. All the above examination data and changes will be analyzed to assess the value of cardiovascular imaging in the pathogenesis, diagnosis, and prognosis of Kawasaki disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06641817
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kawasaki Disease
Currently open trials in the same condition.
- NCT05643651 — Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease · Phase 4 · recruiting
- NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
- NCT07291245 — Kawasaki MATCH Trial · NA · recruiting
- NCT06978439 — Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease · Phase 4 · recruiting
- NCT06993636 — Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years · recruiting
Other West China Second University Hospital trials
Trials by the same sponsor.
- NCT07371182 — Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions · NA · recruiting
- NCT07511920 — A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children · not yet recruiting
- NCT07508072 — Comparison of High-Definition Electronic Magnifying Endoscopy With Image-Enhanced Technology Versus Colposcopy in the De · NA · not yet recruiting
- NCT07431060 — Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis · NA · recruiting
- NCT07201259 — Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Follo · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06641817 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Second University Hospital
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06641817.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing